VASOPRESSIN IN DEXTROSE 5%: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gland	VASOPRESSIN IN DEXTROSE 5%	vasopressin	SOLUTION;INTRAVENOUS	216963	ANDA	Sagent Pharmaceuticals	25021-474-01	25 VIAL in 1 CARTON (25021-474-01) / 1 mL in 1 VIAL	2024-11-15
Gland	VASOPRESSIN IN DEXTROSE 5%	vasopressin	SOLUTION;INTRAVENOUS	216963	ANDA	Gland Pharma Limited	68083-520-10	10 VIAL in 1 CARTON (68083-520-10) / 1 mL in 1 VIAL	2024-02-09
Gland	VASOPRESSIN IN DEXTROSE 5%	vasopressin	SOLUTION;INTRAVENOUS	216963	ANDA	Gland Pharma Limited	68083-520-25	25 VIAL in 1 CARTON (68083-520-25) / 1 mL in 1 VIAL	2024-02-09
Gland	VASOPRESSIN IN DEXTROSE 5%	vasopressin	SOLUTION;INTRAVENOUS	216963	ANDA	Gland Pharma Limited	68083-663-10	10 VIAL in 1 CARTON (68083-663-10) / 100 mL in 1 VIAL	2025-08-22
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: October 18, 2025

Introduction

Vasopressin in dextrose 5% (D5W) is a critical medication used in various clinical settings, including management of diabetes insipidus, vasodilatory shock, and certain cardiac emergencies. As a synthetic analogue of the hormone vasopressin, it regulates water retention and vasoconstriction. Given its importance, reliable sourcing from reputable suppliers is essential for healthcare providers, hospitals, and pharmaceutical distributors. This article offers a comprehensive overview of key suppliers specializing in vasopressin in dextrose 5%, exploring manufacturing sources, market landscape, and supply chain considerations.

Manufacturers of Vasopressin in Dextrose 5%

While vasopressin itself is a well-established peptide hormone, its formulation in dextrose 5% solutions is typically produced by a select group of global pharmaceutical companies, either as branded or sterile injectable formulations. The production processes involve complex peptide synthesis and strict sterilization procedures to ensure safety and efficacy.

1. Ferring Pharmaceuticals

Ferring Pharmaceuticals is a leading international biotech company specializing in reproductive health, urology, and endocrinology. They manufacture Vasopressin Injection (Pitressin®), which is often supplied as a proprietary formulation suitable for hospital use. Although their flagship product is not always explicitly labeled in dextrose 5%, they produce formulations compatible for admixture.

Key Highlights:

Established in Switzerland, with manufacturing facilities adhering to stringent GMP standards.
Supplies both branded and generic vasopressin formulations globally.
Focuses on high-purity peptide-based products, ensuring consistency and safety.

2. Hospira (a Pfizer company)

Hospira has historically been a significant supplier of injectable vasopressin formulations, including formulations suitable for mixing with dextrose solutions.

Key Highlights:

Part of Pfizer’s global portfolio after its acquisition of Hospira in 2015.
Offers vasopressin injection under the Vasopressin® brand.
Known for reliable manufacturing and extensive distribution networks.

3. Sagent Pharmaceuticals

Sagent Pharmaceuticals produces sterile injectable drugs, including vasopressin formulations. Their focus on hospital and institutional supplies makes them a notable supplier in the space.

Key Highlights:

Extensive portfolio of generic injectables.
Focuses on high-quality, cost-effective formulations.
Supplies to North America predominantly, with some international distribution.

4. Teva Pharmaceutical Industries

Teva is one of the world’s largest generic drug manufacturers, producing vasopressin as part of their cardiovascular and endocrine drug lines.

Key Highlights:

Produces licensed vasopressin products compatible with dextrose solutions.
Known for affordability and widespread availability.
Strict adherence to international GMP standards.

5. other regional suppliers and generic manufacturers

Numerous regional generic drug manufacturers also produce vasopressin formulations, especially in Europe, Asia, and Latin America. Examples include:

Mundipharma (Europe)
Sun Pharmaceutical Industries (India)
Aurobindo Pharma (India)
Sandoz (Novartis’ generic division)

Note: The availability and regulatory approval of these generics may vary based on local markets; verification with local regulatory bodies is advised.

Supply Chain and Market Dynamics

The supply of vasopressin in dextrose 5% is influenced by manufacturing capacity, regulatory status, and global demand. As a biologically derived peptide, production bottlenecks can occur due to complex synthesis and purification processes. Additionally, recent global supply chain disruptions, such as those caused by the COVID-19 pandemic, have intermittently impacted availability and increased costs.

Hospitals and distributors often secure supply through multiple suppliers to mitigate shortages. Regulatory approvals, such as FDA approval in the U.S., EMA authorization in Europe, and other regional certifications, significantly influence supplier eligibility.

Emerging Trends and Market Considerations

Generic proliferation: The expiration of patents and regulatory pathways for generic vasopressin formulations have increased options for hospitals and suppliers, exerting downward pressure on prices.
Regulatory compliance: Suppliers maintaining stringent quality standards and compliance with GMP are prioritized, especially when supplied in critical care settings.
Formulation stability: The formulation in dextrose 5% requires stability over shelf life; suppliers focus on rigorous quality control to ensure potency and safety.
Biosimilar development: Although vasopressin is a small peptide, biosimilar development is limited but potentially emerging, which could alter the competitive landscape.

Key Factors for Procurement Decisions

Regulatory approval: Ensuring the supplier’s product is approved by relevant authorities.
Supply stability: Ability to meet fluctuating demands during crises or seasonal peaks.
Price competitiveness: Cost-effectiveness without compromising quality.
Quality assurance: Adherence to GMP and sterilization standards.
Distribution network: Efficient logistics for timely delivery.

Conclusion

Identifying reliable suppliers for vasopressin in dextrose 5% requires navigating a landscape of global pharmaceutical manufacturers, regional generic producers, and regulatory frameworks. Leading companies like Ferring Pharmaceuticals, Pfizer (Hospira), Sagent Pharmaceuticals, and Teva dominate the market through their established manufacturing capabilities and extensive distribution networks. Healthcare providers should prioritize suppliers with proven quality standards and regulatory approvals to ensure safety and efficacy.

Given ongoing market dynamics, procurement professionals must stay abreast of supply chain developments and regulatory changes to mitigate potential shortages and optimize sourcing strategies.

Key Takeaways

Major global suppliers include Ferring Pharmaceuticals, Pfizer (Hospira), Sagent Pharmaceuticals, and Teva.
Regional and generic manufacturers also contribute significantly, especially in emerging markets.
Supply reliability is affected by manufacturing complexity, regulatory approval, and global logistics.
Hospital procurement should verify GMP compliance and regional approvals before engaging suppliers.
Market trends suggest increasing availability of generics and biosimilars, influencing pricing and supply stability.

FAQs

1. How can I verify the authenticity and quality of vasopressin in dextrose 5% from suppliers?
Always source from suppliers with verified GMP certification and regulatory approval. Request documentation such as lot release certificates, COAs (Certificates of Analysis), and regulatory approvals to ensure authenticity and quality.

2. Are there biosimilar versions of vasopressin available?
Currently, biosimilars for vasopressin are limited, as it is a small peptide hormone. Development exists but has yet to significantly impact the market. Most supplies stem from branded and generic formulations.

3. What are the typical delivery considerations for vasopressin in dextrose 5%?
Vasopressin solutions require strict cold chain and aseptic handling. Suppliers must guarantee sterility, stability, and timely delivery to prevent shortages or product degradation.

4. Is vasopressin in dextrose 5% approved for use worldwide?
Approval depends on regional regulatory agencies. It is widely approved in the United States (by the FDA), Europe (by EMA), and other jurisdictions, though regional regulations may vary.

5. How will market trends influence future sourcing strategies?
Increasing generic competition and biosimilar development are likely to expand options, reduce costs, and improve supply stability. Staying updated with regulatory changes and supplier innovations will be critical for strategic sourcing.

Sources:

[1] Pharmacopoeia of the United States. U.S. Pharmacopeia – USP 45. 2022.
[2] Ferring Pharmaceuticals Official Website. (https://www.ferring.com)
[3] Pfizer Corporate Website. (https://www.pfizer.com)
[4] Sagent Pharmaceuticals Official Website. (https://www.sagentpharma.com)
[5] Teva Pharmaceuticals Official Website. (https://www.teva.com)

Suppliers and packagers for VASOPRESSIN IN DEXTROSE 5%